Psilera Unveils Novel, Non-Hallucinogenic Psilocybin Derivative PSIL-006 As Lead Clinical Candidate ...Middle East

PR Newswire - News
Psilera Unveils Novel, Non-Hallucinogenic Psilocybin Derivative PSIL-006 As Lead Clinical Candidate
PSIL-006 is the first drug candidate from Psilera's extensive pipeline to progress into advanced safety studies prior to first-in-human clinical trials TAMPA, Fla., May 25, 2023 /PRNewswire/ -- Psilera, a biopharmaceutical company developing next-generation mental health treatments for...

Hence then, the article about psilera unveils novel non hallucinogenic psilocybin derivative psil 006 as lead clinical candidate was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Psilera Unveils Novel, Non-Hallucinogenic Psilocybin Derivative PSIL-006 As Lead Clinical Candidate )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News
Parade - before 11 hour & 42 minute